Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opening Session Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Apr
22
Today In Oncology
2024 Annual Report to the Nation on the Status of Cancer Released
Adaptive Manufactured Lentiviral Anti-CD20 Anti-CD19 CAR T Cells in Relapsed Refractory Mantle Cell Lymphoma
Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma Lessons From CML
Updated CAP Guideline Aims to Address Rising Rates of HPV Associated Squamous Cell Carcinomas
Patient Support Found for AI Use as Second Reader of Mammograms
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo